TDM doesn’t improve outcomes in patients starting TNFi

Therapeutic drug monitoring (TDM) doesn’t appear to improve clinical outcomes in patients starting infliximab therapy, a European study suggests. The Norwegian Drug Monitoring Trial (NOR-DRUM) is believed to be the first RCT to compare TDM versus a standard approach to dosing in patients with any approved indication for infliximab. Part A of the study randomised ...

Already a member?

Login to keep reading.

© 2021 the limbic